Altium Capital Management LP Chinook Therapeutics, Inc. Transaction History

Altium Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $1.72 Million - $2.14 Million	-80,000 Reduced 20.78%	305,000 $7.06 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $2.61 Million - $3.83 Million	-140,000 Reduced 26.67%	385,000 $10.1 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $1.58 Million - $2.1 Million	-90,000 Reduced 14.63%	525,000 $10.3 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $881,300 - $1.32 Million	70,000 Added 12.84%	615,000 $10.8 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $855,200 - $1.35 Million	80,000 Added 17.2%	545,000 $8.89 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $556,979 - $719,714	48,433 Added 11.63%	465,000 $5.26 Million
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $2.87 Million - $4 Million	210,768 Added 102.41%	416,567 $5.88 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $2.45 Million - $4.3 Million	205,799 New	205,799 $3.26 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.